Early Stage Breast Cancer clinical trials

Explore recruiting early stage breast cancer clinical trials.

Recruiting early stage breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Early Stage Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Diagnostic HER2DX-guided trEatment For patIeNts wIth early-sTage HER2-positIVE breast cancer

Germany, Ireland, France, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2)

Spain, Germany, Hungary, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomized phase 3 trial

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (TDXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)

Spain, Germany, Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Early Stage Breast Cancer trials by city

Early Stage Breast Cancer in Toronto Early Stage Breast Cancer in Vancouver Early Stage Breast Cancer in Montreal Early Stage Breast Cancer in Calgary Early Stage Breast Cancer in Edmonton Early Stage Breast Cancer in Ottawa Early Stage Breast Cancer in Winnipeg Early Stage Breast Cancer in Quebec City Early Stage Breast Cancer in Hamilton Early Stage Breast Cancer in Kitchener Early Stage Breast Cancer in London Early Stage Breast Cancer in Halifax Early Stage Breast Cancer in New York Early Stage Breast Cancer in Los Angeles Early Stage Breast Cancer in Chicago Early Stage Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease